Vera Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
VERA$30.03-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(51,694) | $(28,383) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 85 | 11 |
| Accretion of discount and amortization of premium on purchase of debt securities | (2,531) | (1,669) |
| Accretion of loan exit fee and amortization of loan costs | 221 | 189 |
| Reduction in the carrying amount of operating lease right-of-use assets | 457 | 517 |
| Stock-based compensation | 7,744 | 4,124 |
| Payment of VT-109 license fee | 750 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expense and other current assets | (5,876) | (392) |
| Other assets | 17 | 9 |
| Accounts payable | 1,597 | (5,909) |
| Accrued and other liabilities | (4,782) | (1,690) |
| Operating lease liabilities | (394) | (637) |
| Net cash used in operating activities | (54,406) | (33,830) |
| Cash flows from investing activities | ||
| Payment of VT-109 license fee | (750) | — |
| Purchase of property and equipment | (187) | — |
| Purchase of marketable securities | (89,992) | (254,967) |
| Proceeds from maturities of marketable securities | 106,246 | 31,681 |
| Proceeds from sale of marketable securities | — | 4,000 |
| Net cash provided by (used in) investing activities | 15,317 | (219,286) |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 1,533 | 6,911 |
| Proceeds from short swing settlement | — | 37 |
| Proceeds from issuance of common stock in follow-on offering | — | 287,500 |
| Payment of issuance costs and underwriting fees related to follow-on offerings | — | (17,908) |
| Net cash provided by financing activities | 1,533 | 276,540 |
| Net (decrease) increase in cash and cash equivalents | (37,556) | 23,424 |
| Cash and cash equivalents, beginning of period | 92,646 | 45,681 |
| Cash and cash equivalents, end of period | $55,090 | $69,105 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest expense | $1,581 | $1,520 |
| Receivable on exercise of stock options | $— | $13 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.